Business Context and Reporting Period
Company: Palisade Bio, Inc. (PALI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases. Its lead product candidate, PALI-2108, is being developed for inflammatory bowel disease (IBD), including fibrostenotic Crohn's disease and ulcerative colitis. The company operates as a single segment and is classified as a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(2,784) | $(4,080) | $(5,014) | $(7,607) |
| Loss Per Share (Basic/Diluted) | $(0.58) | $(3.32) | $(1.05) | $(7.60) |
| Cash and Cash Equivalents (End of Period) | $5,417 | $11,353 | $5,417 | $11,353 |
| Accumulated Deficit | $(140,958) | $(129,113) | $(140,958) | $(129,113) |
| Net Cash Used in Operating Activities (YTD) | $(4,150) | $(6,679) | $(4,150) | $(6,679) |
| Insurance Financing Debt | $314 | $79 | $314 | $79 |
Note: The company has no product revenue. Operating expenses consist primarily of Research and Development (R&D) and General and Administrative (G&A) costs.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 32% in Q2 2025 ($2.8M) compared to Q2 2024 ($4.2M). This was driven by a 36% drop in R&D expenses and a 26% drop in G&A expenses.
- R&D Drivers: The decrease in R&D is primarily due to the cessation of preclinical joint development costs with partner Giiant Pharma (approx. $1.9M reduction), partially offset by increased clinical trial expenses ($1.1M increase) as the company assumed full responsibility for PALI-2108 development following Phase 1 approval.
- G&A Drivers: G&A reductions were largely due to the absence of non-cash share-based compensation expenses related to accelerated RSU vesting that occurred in Q2 2024, and reduced consultant fees.
- Liquidity: Cash and cash equivalents declined from $9.8M at year-end 2024 to $5.4M at June 30, 2025, reflecting a net cash burn of $4.2M in the first half of 2025.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management does not provide specific financial guidance but states that current cash resources ($5.4M) combined with proceeds from a subsequent warrant inducement transaction (see below) are expected to fund operations into the first quarter of 2026. Additional financing will be required thereafter to continue operations.
Subsequent Events (Post-June 30, 2025)
On July 23, 2025, the company entered into a warrant inducement agreement, closing on July 25, 2025. This transaction generated gross cash proceeds of approximately $3.9 million from the exercise of 4.3 million existing warrants. The company issued replacement warrants to the holder.
Risks and Contingencies
- Going Concern: The filing explicitly states there is "substantial doubt" about the company's ability to continue as a going concern for one year following the issuance date due to recurring losses and negative cash flows.
- Internal Controls: A material weakness in internal control over financial reporting remains unremediated as of June 30, 2025, related to financial closing processes and segregation of duties.
- Regulatory: The company received a notice from Nasdaq on April 30, 2025, regarding non-compliance with the $1.00 minimum bid price requirement. While the stock briefly met the requirement in August 2025, Nasdaq is continuing to monitor the situation. Failure to maintain compliance could lead to delisting.
- Development Risk: Success depends entirely on the clinical development of PALI-2108. The company is currently conducting a Phase 1 trial in Canada and plans to submit an IND for U.S. trials in the first half of 2026.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.4M cash balance plus the $3.9M subsequent warrant proceeds to fund the planned Phase 1b and Phase 2 trials through Q1 2026.
- Going Concern Status: Assess the likelihood of securing additional equity or debt financing before Q1 2026 given the "substantial doubt" disclosure.
- Nasdaq Compliance: Monitor the stock price to ensure it maintains the $1.00 minimum bid price to avoid delisting proceedings.
- Internal Controls: Review the progress of remediation efforts for the material weakness in internal controls over financial reporting.
- Clinical Progress: Track the timeline for the submission of the U.S. Investigational New Drug (IND) application and the initiation of Phase 2 studies.